Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
It has been known for some time that key genetic changes are the principle mechanism of cancer development. These changes lead to abnormalities in the signalling pathways of cells and result in unregulated cell growth, angiogenesis and metastasis.
Dear
Rachel
R
Medical Oncology, Westmead and Nepean Hospitals, New South Wales. rachshaw@hotmail.com
Wilcken
Nicholas
N
Shannon
Jenny
J
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D004347:Drug Interactions; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D008967:Molecular Biology / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor; D000068878:Trastuzumab